Lessons learned from development of docetaxel

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 7, 2008, Pages 1007-1019

  Strother, Robert Matthew ^a   Sweeney, Christopher ^b  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Breast cancer; Chemotherapeutic; Docetaxel; Taxoid

Indexed keywords

ANGIOGENESIS INHIBITOR; CAPECITABINE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; DRUG METABOLIZING ENZYME; ENDOTHELIN A RECEPTOR ANTAGONIST; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; KETOCONAZOLE; LANIQUIDAR; METHOTREXATE; MITOXANTRONE; NAVELBINE; OROSOMUCOID; PACLITAXEL; PLATINUM COMPLEX; PREDNISONE; RITONAVIR; STEROID; TRASTUZUMAB; VINDESINE; VITAMIN D DERIVATIVE;

ASCITES; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EFFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FIRST PASS EFFECT; FLUID RETENTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEAD AND NECK CANCER; HUMAN; HYPOXIA; LACRIMATION DISORDER; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MONOTHERAPY; NAIL DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PHARMACOGENETICS; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SENSORY NEUROPATHY; SEX DIFFERENCE; SIDE EFFECT; SKIN DISEASE; STOMACH CANCER; SURVIVAL TIME; UTERINE CERVIX CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; FEMALE; HUMANS; NEOPLASMS; PHARMACOGENETICS; TAXOIDS;

EID: 49649120909     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.7.1007     Document Type: Review

References (123)

1. Karantanis E, Nicholson S, Morris DL. Taxotere inhibits in vitro growth of human colonic cancer cell lines. Eur J Surg Oncol 1994;20(6):653-7
2. Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1992;30(6):444-50
3. Kreis W, Budman DR, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 1997;79(2):196-202
4. Rangel C, Niell H, Miller A, Cox C. Taxol and taxotere in bladder cancer: in vitro activity and urine stability. Cancer Chemother Pharmacol 1994;33(6):460-4
5. Riccardi A, Servidei T, Tornesello A, et al. Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines. Eur J Cancer 1995;31A(4):494-9
6. Silvestrini R, Zaffaroni N, Orlandi L, Oriana S. In vitro cytotoxic activity of Taxol and Taxotere on primary cultures and established cell lines of human ovarian cancer. Stem Cells 1993;11(6):528-35
7. Tanaka M, Obata T, Sasaki T. Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo. Eur J Cancer 1996;32A(2):226-30
8. Consolini R, Pui CH, Behm FG, et al. In vitro cytotoxicity of docetaxel in childhood acute leukemias. J Clin Oncol 1998;16(3):907-13
9. Dykes DJ, Bissery MC, Harrison SD Jr, Waud WR. Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere). Invest New Drugs 1995;13(1):1-11
10. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 1998;9(1):1-17
11. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I. Preclinical experience. Anticancer Drugs 1995;6(3):339-55, 63-8
12. Bissett D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 1993;53(3):523-7
13. Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993;11(5):950-8
14. Pazdur R, Newman RA, Newman BM, et al. Phase I trial of Taxotere: five-day schedule. J Natl Cancer Inst 1992;84(23):1781-8
15. Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 1994;12(7):1458-67
16. Extra JM, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993;53(5):1037-42
17. Bruno R, Sanderink GJ. Pharmacokinetics and metabolism of Taxotere (docetaxel). Cancer Surviv 1993;17:305-13
18. ten Bokkel Huinink WW, Prove AM, Piccart M, et al. A Phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 1994;5(6):527-32
19. Ravdin PM, Burris HA 3rd, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13(12):2879-85
20. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13(12):2886-94
21. Adachi I, Watanabe T, Takashima S, et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 1996;73(2):210-6
22. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12
23. Dagher R, Li N, Abraham S, et al. Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 2004;10(24):8147-51
24. Hahn NM, Marsh S, Fisher W, et al. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res 2006;12(20 Pt 1):6094-9
25. Nagao S, Fujiwara K, Oda T, et al. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol 2005;96(3):805-9
26. Garcia AA, Blessing JA, Vaccarello L, Roman LD. Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Am J Clin Oncol 2007;30(4):428-31
27. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24(31):4991-7
28. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007;25(22):3210-6
29. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357(17):1705-15
30. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357(17):1695-704
31. Alexandre J, Bleuzen P, Bonneterre J, et al. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 2000;18(3):562-73
32. Engels FK, Venweij J. Docetaxel administration schedule: from fever to tears? A review of randomized studies. Eur J Cancer 2005;41(8):1117-26
33. Georgoulias V, Androulakis N, Kotsakis A, et al. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer 2008;59(1):57-63
34. Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006;24(36):5664-71
35. Markman M. Managing taxane toxicities. Support Care Cancer 2003;11(3):144-7
36. Kouroussis C, Mavroudis D, Kakolyris S, et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer 2004;44(3):363-8
37. Schrijvers D, Wanders J, Dirix L, et al. Coping with toxicities of docetaxel (Taxotere). Ann Oncol 1993;4(7):610-1
38. Rosing H, Lustig V, Koopman FP, et al. Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction. J Chromatogr B Biomed Sci Appl 1997;696(1):89-98
39. Vergniol JC, Bruno R, Montay G, Frydman A. Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromarographic method. J Chromatogr 1992;582(1-2):273-8
40. Loos WJ, Verweij J, Nooter K, et al. Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997;693(2):437-41
41. Ciccolini J, Catalin J, Blachon MF, Durand A. Rapid high-performance liquid chromatographic determination of docetaxel (Taxotere) in plasma using liquid-liquid extraction. J Chromatogr B Biomed Sci Appl 2001;759(2):299-306
42. Garg MB, Ackland SP. Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. J Chromatogr B Biomed Sci Appl 2000;748(2):383-8
43. Parise RA, Ramanathan RK, Zamboni WC, Egorin MJ. Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2003;783(1):231-6
44. Wang LZ, Goh BC, Grigg ME, et al. A rapid and sensitive liquid chromatography/tandem mass spectrometry method for determination of docetaxel in human plasma. Rapid Commun Mass Spectrom 2003;17(14):1548-52
45. Kuppens IE, van Maanen MJ, Rosing H, et al. Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry: Biomed Chromatogr 2005;19(5):355-61
46. Gustafson DL, Long ME, Zirrolli JA, et al. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Cancer Chemother Pharmacol 2003;52(2):159-66
47. Zufia Lopez L, Aldaz Pastor A, Aramendia Beitia JM, et al. Determination of docetaxel and Paclitaxel in human plasma by high-performance liquid chromatography: validation and application to clinical pharmacokinetic studies. Ther Drug Monit 2006;28(2):199-205
48. Mortier KA, Lambert WE. Determination of unbound docetaxel and paclitaxel in plasma by ultrafiltration and liquid chromatography-tandem mass spectrometry: J Chromatogr A 2006;1108(2):195-201
49. Sparreboom A, Zhao M, Brahmer JR, et al. Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry: J Chromatogr B Analyt Technol Biomed Life Sci 2002;773(2):183-90
50. Urien S, Barre J, Morin C, et al. Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs 1996;14(2):147-51
51. Kumar GN, Walle UK, Bhalla KN, Walle T. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol 1993;80(3):337-44
52. ten Tije AJ, Loos WJ, Zhao M, et al. Limited cerebrospinal fluid penetration of docetaxel. Anticancer Drugs 2004;15(7):715-8
53. Minami H, Kawada K, Sasaki Y, et al. Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients. Cancer Sci 2006;97(3):235-41
54. Baker SD, Li J, ten Tije AJ, et al. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther 2005;77(1):43-53
55. Hooker A, Ten Tije A, Carducci M, et al. Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P450 3A activity measurements. Clin Pharmacol Ther 2008;1-8 (online published January 9, 2008)
56. Laos WJ, Baker SD, Verweij J, et al. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther 2003;74(4):364-71
57. van Tellingen O, Beijnen JH, Verweij J, et al. Rapid estetase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin Cancer Res 1999;5(10):2918-24
58. van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001;19(2):125-41
59. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36(2):99-114
60. Sparreboom A, Van Tellingen O, Scherrenburg EJ, et al. Isolation, purification and biological activity of major docetaxel metabolites from human feces. Drug Metab Dispos 1996;24(6):655-8
61. Marre F, Sanderink GJ, de Sousa G, et al. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996;56(6):1296-302
62. Hirth J, Watkins PB, Strawderman M, et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000;6(4):1255-8
63. Alexandre J, Rey E, Girre V, et al. Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Ann Oncol 2007;18(1):168-72
64. Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002;20(17):3683-90
65. Royer I, Monsarrat B, Sonnier M, et al. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996;56(1);:58-65
66. Yamamoto N, Tamura T, Kamiya Y, et al. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 2000;18(11):2301-8
67. van Zuylen L, Verweij J, Nooter K, et al. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 2000;6(7):2598-603
68. McLeod HL, Kearns CM, Kuhn JG, Bruno R. Evaluation of the linearity of docetaxel pharmacokinetics. Cancer Chemother Pharmacol 1998;42(2):155-9
69. Baille P, Bruno R, Schellens JH, et al. Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance. Clin Cancer Res 1997;3(9):1535-8
70. Rudek MA, Sparreboom A, Garrett-Mayer ES, et al. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer 2004;40(8):1170-8
71. Hochegger K, Lhotta K, Mayer G, et al. Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer. Nephrol Dial Transplant 2007;22(1):289-90
72. ten Tije AJ, Verweij J, Carducci MA, et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 2005;23(6):1070-7
73. Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 2005;104(12):2766-74
74. Kaira K, Tsuchiya S, Sunaga N, et al. A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer. Am J Clin Oncol 2007;30(1):51-6
75. Hurria A, Fleming MT, Baker SD, et al. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 2006;12(20 Pt 1):6100-5
76. LeCaer H, Barlesi F, Robinet G, et al. An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: the GFPC 02-02b study. Lung Cancer 2007;57(1):72-8
77. Takigawa N, Segawa Y, Kishino D, et al. Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients. Cancer Chemother Pharmacol 2004;54(3):230-6
78. Duche JC, Urien S, Simon N, et al. Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer. Clin Biochem 2000;33(3):197-202
79. Bruno R, Olivares R, Berille J, et al. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin Cancer Res 2003;9(3):1077-82
80. Charles KA, Rivory LP, Stockler MR, et al. Predicting the toxicity of weekly docetaxel in advanced cancer. Clin Pharmacokinet 2006;45(6):611-22
81. Puisset F, Alexandre J, Treluyer JM, et al. Clinical pharmacodynamic factors in docetaxel toxicity. Br J Cancer 2007;97(3):290-6
82. Tran A, Jullien V, Alexandre J, et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006;79(6):570-80
83. Bosch TM, Huitema AD, Doodeman VD, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 2006;12(19):5786-93
84. Lewis LD, Miller AA, Rosner GL, et al. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res 2007;13(11):3302-11
85. Watters JW, Kraja A, Meucci MA, et al. Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci USA 2004;101(32):11809-14
86. Engels FK, Ten Tije AJ, Baker SD, et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 2004;75(5):448-54
87. Baumhakel M, Kasel D, Rao-Schymanski RA, et al. Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther 2001;39(12):517-28
88. Nallani SC, Genter MB, Desai PB. Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel. Cancer Chemother Pharmacol 2001;48(2):115-22
89. Nallani SC, Goodwin B, Buckley AR, et al. Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes. Cancer Chemother Pharmacol 2004;54(3):219-29
90. Baker AF, Dorr RT. Drug interactions with the taxanes: clinical implications. Cancer Treat Rev 2001;27(4):221-33
91. Baker SD. Drug interactions with the taxanes. Pharmacotherapy 1997;17(5 Pt 2):126S-132S
92. Engels FK, Mathot RA, Loos WJ, et al. Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. Cancer Biol Ther 2006;5(7):833-9
93. Engels FK, Loos WJ, Mathot RA, et al. Influence of ketoconazole on the fecal and urinary disposition of docetaxel. Cancer Chemother Pharmacol 2007;60(4):569-79
94. Bardelmeijer HA, Ouwehand M, Buckle T, et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002;62(21):6158-64
95. Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL. A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res 2007;13(9):2768-76
96. Veyrat-Follet C, Bruno R, Olivares R, et al. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 2000;68(6):677-87
97. Chang JC, Makris A, Gutierrez MC, et al. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat 2008;108(2):233-40 [Epub 2007 Apr 28]
98. Mina L, Soule SE, Badve S, et al. Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Res Treat 2007;103(2):197-208
99. Bernard-Marty C, Treilleux I, Dumontet C, et al. Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin Breast Cancer 2002;3(5):341-5
100. Martin M, Pienkowski T, MacKey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352(22):2302-13
101. Goldstein LJ, O'Neill A, Sparano J, et al. E2197: phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. J Clin Oncol 2005;23:512
102. Sparano JA WM, Martino S, Jones V, et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. San Antonio Breast Cancer Symposium; 2005 December 8 - 11; San Antonio, TX
103. Francis P, Crown J, Di Leo A, et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 2008;100(2):121-33
104. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20
105. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24:5381-7
106. Robert NJ EW, Pienkowski T, Crown J, et al. on behalf of the BCIRG 006 Investigators. BCIRG 006: Docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: Quality of life (QOL) at 36 months follow-up. J Clin Oncol 2007;25(18S):[Abstract 19647]
107. Sjostrom J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999;35(8):1194-201
108. Bonneterre J, Roche H, Monnier A, et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002;87(11):1210-5
109. Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003;21(6):968-75
110. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23(24):5542-51
111. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20(12):2812-23
112. Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004;96(10):759-69
113. Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004;91(12):1996-2004
114. Kubota K, Watanabe K, Kunitoh H, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004;22(2):254-61
115. Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005;16(4):602-10
116. Camps C, Massuti B, Jimenez A, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 2006;17(3):467-72
117. Hainsworth JD, Spigel DR, Farley C, et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 2007;110(9):2027-34
118. Miller VA, Rigas JR, Francis PA, et al. Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995;75(4):968-72
119. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21(16):3016-24
120. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-8
121. Rebattu P, Quantin X, Ardiet C, et al. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Lung Cancer 2001;33(2-3):277-87
122. Schuette W, Nagel S, Blankenburg T, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005;23(33):8389-95
123. Di Maio M, Perrone F, Chiodini P, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2007;25(11):1377-82